Alternate Medicine Startup, Welcome Cure Raises Pre-Series A funding of $6mn

Company Name : Welcome Cure
Funding Amount : $6mn
Funding Round : Pre-Series A

Welcome Cure, one of the first and only global and innovative health care technology platform focused on alternate medicine, has raised USD 6mn in pre-series A funding from a pool of investors. The company has raised USD 1mn from few high net-worth individuals and USD 5mn from one of India’s largest media house. The amount will be invested in the health care portal’s on-going expansion and marketing strategies.

Welcome Cure offers homeopathic treatment to people globally, regardless of language, location and time barriers. It has been co-founded by Dr. Jawahar J. Shah and Punit Desai. Dr. Shah is an award-winning homeopathic practitioner, technocrat, educationalist and academician with over 39 years of experience in the field of homeopathy, while Punit is a successful entrepreneur with vast experience, investments and capabilities in solar power, e-commerce & home shopping, films, media and entertainment sectors.

Welcome Cure is a virtual clinic offering modern facilities of online consultation via video chat, live chat, Skype, telephonic and email interactions with expert physicians worldwide, at consumer convenience. Users can avail digital health consultation with the door step delivery of medicines. In addition to this, case histories and medical reports are also digitized with free storage for lifetime. Periodic reminders and trackers, amazing facts, health tips and diet plans further form a part of the unique features of the health care portal.

Welcome Cure boasts of a network of over 100 world class renowned doctors registered from across the globe, providing unlimited treatment for over 100 diseases under one digital roof. The site also offers pocket-friendly health packages varying from three months to two years for their users, making it an end to end online homeopathy platform through the web portal and mobile application.

Welcome Cure was launched in late 2014 after a year of extensive research, development and execution. The company follows processes that adhere to the global standards of HIPAA and HL7 security and strict international norms while managing patients.